ERBB2 and gastric cancer: EAC, GC, and CRC were divided into three groups: group 1 comprised samples with both ERBB2 mutations and amplifications, group 2 comprised samples with ERBB2 mutations annotated as putative driver mutations by OncoKB but without amplifications, and group 3 consisted of samples evaluated as non-driver mutations (passenger mutations or unknown significance) by OncoKB and those that were not amplified.